2021
DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo
Tymon-Rosario J, Bonazzoli E, Bellone S, Manzano A, Pelligra S, Guglielmi A, Gnutti B, Nagarkatti N, Zeybek B, Manara P, Zammataro L, Harold J, Mauricio D, Buza N, Hui P, Altwerger G, Menderes G, Ratner E, Clark M, Andikyan V, Huang GS, Silasi DA, Azodi M, Schwartz PE, Santin AD. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. Gynecologic Oncology 2021, 163: 334-341. PMID: 34452746, PMCID: PMC8722447, DOI: 10.1016/j.ygyno.2021.08.014.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedBenzodiazepinesBystander EffectCell Line, TumorCystadenocarcinoma, SerousDrug Resistance, NeoplasmFemaleHumansImmunoconjugatesMiddle AgedPrimary Cell CultureReceptor, ErbB-2TrastuzumabUterine NeoplasmsXenograft Model Antitumor AssaysConceptsHER2/neuPrimary USC cell linesUSC cell linesUterine serous carcinomaSerous carcinomaHER2/Cell linesBystander killingHER2/neu protein expressionHER2/neu overexpressionProtein expressionNovel treatment optionsAggressive histologic variantNeu protein expressionHER2 protein expressionC-erbB2 gene amplificationSignificant bystander killingUSC xenograftsEndometrial cancerNegative tumorsPoor prognosisPositive tumorsTreatment optionsPreclinical activityHistologic variants
2018
FOXL2 Mutation Analysis of Ovarian Sex Cord-Stromal Tumors
Buza N, Wong S, Hui P. FOXL2 Mutation Analysis of Ovarian Sex Cord-Stromal Tumors. International Journal Of Gynecological Pathology 2018, 37: 305-315. PMID: 28700438, DOI: 10.1097/pgp.0000000000000426.Peer-Reviewed Original ResearchConceptsSex cord-stromal tumorsAdult granulosa cell tumorGranulosa cell tumorsOvarian sex cord-stromal tumorsCell tumorsReticulin patternFOXL2 mutationStaining patternSertoli-Leydig cell tumorFOXL2 mutation statusAbundant pale cytoplasmSingle institutional cohortThird of casesWild-type tumorsFOXL2 mutation analysisNegative tumorsPositive tumorsTumor sizeReticulin stainingType tumorsPale cytoplasmNuclear atypiaMutation statusPositive casesTumors